Cannabinoids are promising therapies to support neurogenesis and decelerate disease progression in neuroinflammatory and degenerative disorders. Whether neuroprotective effects of cannabinoids are sustainable during persistent viral infection of the CNS is not known. Using a rodent model of chronic viral encephalitis based on Borna Disease (BD) virus, in which 1 week treatment with the general cannabinoid WIN 55,212-2 has been shown to be neuroprotective (Solbrig et al., 2010), we examine longer term (2 week treatment) effects of a general (CB₁ and CB₂) cannabinoid receptor agonist WIN55,212-2 (1mg/kg ip twice per day) or a specific (CB₂) cannabinoid receptor agonist HU-308 (5mg/kg ip once daily) on histopathology, measures of frontostriatal neurogenesis and gliogenesis, and viral load. We find WIN and HU-308 differ in their ability to protect new BrdU⁺ cells. The selective CB₂ agonist HU increases BrdU⁺ cells in prefrontal cortex (PFC), significantly increases BrdU⁺ cells in striatum, differentially regulates polydendrocytes vs microglia/macrophages, and reduces immune activation at a time WIN-treated rats appear tolerant to the anti-inflammatory effect of their cannabinoid treatment. WIN and HU had little direct viral effect in PFC and striatum, yet reduced viral signal in hippocampus. Thus, HU-308 action on CB₂ receptors, receptors known to be renewed during microglia proliferation and action, is a nontolerizing mechanism of controlling CNS inflammation during viral encephalitis by reducing microglia activation, as well as partially limiting viral infection, and uses a nonpsychotropic cannabinoid agonist.
Copyright © 2013 The Authors. Published by Elsevier B.V. All rights reserved.

PMID:

 

24021420

 

[PubMed – as supplied by publisher]